RxDoctor Payments Data

John Lalonde, DO

Family Medicine · Costa Mesa, CANPI 1942388186

Payments from drug & device makers

$3,404in general payments, 2019–2025

Across 196 payments — averaging $17.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$266
  • Takeda Pharmaceuticals U.S.A., Inc.$163
  • Galderma Laboratories, L.p.$126
  • Novo Nordisk$120
  • Teva Pharmaceuticals USA, Inc.$51
  • plus $372 from 15 others

What the payments were for

  • Food & beverage$3,404100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,404 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$63,785
Medicare patients
205
Services billed
6,535

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide81$82,754
EliquisApixaban60$60,013
MounjaroTirzepatide21$23,292
JanuviaSitagliptin Phosphate20$22,549
XareltoRivaroxaban18$13,960
Ajovy AutoinjectorFremanezumab-Vfrm13$9,074
Emgality PenGalcanezumab-Gnlm12$8,342
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$7,966
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$5,881
VyvanseLisdexamfetamine Dimesylate13$4,913
Levothyroxine Sodium221$2,874
Atorvastatin Calcium259$2,400
Losartan Potassium196$2,214
SynthroidLevothyroxine Sodium25$1,749
Gabapentin76$1,600

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$120$82,75481 claims
PfizerEliquis$266$60,01360 claims
Lilly USA, LLCMounjaro$51$23,29221 claims
MerckJanuvia$12$22,54920 claims
Johnson & JohnsonXarelto$28$13,96018 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$163$4,91313 claims
AbbVieSynthroid$2,305$1,74925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Costa Mesa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →